Further molecular analysis with the Oncomine Comprehensive Assay v3 (OCAv3) and ThyroSPEC (18, 19) revealed an ETV6::NTRK3 fusion-positive tumor harboring an additional TERT promoter mutation c.-124C>T, with no other genetic alterations. This evidence concerns the gene TERT and neoplasm.